Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells

Pathology and Oncology Research

Volumn 17, Issue 3, 2011, Pages 645-656

  Mise, Josko ^a   Dembitz, Vilma ^a   Banfic, Hrvoje ^a   Visnjic, Dora ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

ATRA; Leukemia; PI3K; PMA; Rapamycin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CD11B ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; LEUKEMIA CELL; NONHUMAN;

BLOTTING, WESTERN; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 80052697200     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9365-z     Document Type: Article

References (35)

1. Q Xu SE Simpson TJ Scialla, et al. 2003 Survival of acute myeloid leukemia cells requires PI3 kinase activation Blood 102 972 980 12702506 10.1182/blood-2002-11-3429 1:CAS:528:DC%2BD3sXlvFCmtrs%3D (Pubitemid 36917792)
2. MY Follo S Mongiorgi C Bosi, et al. 2007 The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation Cancer Res 67 4287 4294 17483341 10.1158/0008-5472.CAN-06-4409 1:CAS:528:DC%2BD2sXltVyrsLw%3D (Pubitemid 46815076)
3. J LoPiccolo GM Blumenthal WB Bernstein, et al. 2008 Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations Drug Resist Updat 11 32 50 18166498 10.1016/j.drup.2007.11.003 1:CAS:528: DC%2BD1cXlslWqurw%3D
4. V Papa PL Tazzari F Chiarini, et al. 2008 Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells Leukemia 22 147 160 17928881 10.1038/sj.leu.2404980 1:CAS:528:DC%2BD1cXmsVyqtA%3D%3D
5. G Tabellini PL Tazzari R Bortul, et al. 2004 Novel 2′-substituted, 3′-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway Br J Haematol 126 574 582 15287952 10.1111/j.1365-2141.2004.05073.x 1:CAS:528:DC%2BD2cXnsF2qu7s%3D (Pubitemid 39093101)
6. Richardson P, Wolf JL, Jakubowiak A et al. (2009) Perifosine in combination with bortezomib and dexamethasone extends progression-free survival and overall survival in relapsed/refractory multiple myeloma patients previously treated with bortezombib: updated phase I/II Trial Results. Blood (ASH Ann Meeting Abstracts). 114:1869
7. JK Altman LC Platanias 2008 Exploiting the mammalian target of rapamycin pathway in hematologic malignancies Curr Opin Hematol 15 88 94 18300753 10.1097/MOH.0b013e3282f3deaa 1:CAS:528:DC%2BD1cXjslWitr0%3D (Pubitemid 351323147)
8. PT Bhaskar N Hay 2007 The two TORCs and Akt Dev Cell 12 487 502 17419990 10.1016/j.devcel.2007.03.020 1:CAS:528:DC%2BD2sXksVOhs7c%3D (Pubitemid 46523652)
9. C Récher O Beyne-Rauzy C Demur, et al. 2005 Antileukemic activity of rapamycin in acute myeloid leukemia Blood 105 2527 2534 15550488 10.1182/blood-2004-06-2494 (Pubitemid 40387055)
10. C Nishioka T Ikezoe J Yang, et al. 2008 Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells Leukemia 22 2159 2168 18784743 10.1038/leu.2008.243 1:CAS:528:DC%2BD1cXhsFWjtb7O
11. DA Rizzieri E Feldman JF Dipersio, et al. 2008 A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies Clin Cancer Res 14 2756 2762 18451242 10.1158/1078-0432.CCR-07-1372 1:CAS:528:DC%2BD1cXlsV2qurs%3D
12. KW Yee Z Zeng M Konopleva, et al. 2006 Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies Clin Cancer Res 12 5165 5173 16951235 10.1158/1078-0432.CCR-06-0764 1:CAS:528:DC%2BD28XovF2gsLc%3D (Pubitemid 44453345)
13. MG Kharas MR Janes VM Scarfone, et al. 2008 Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL + leukemia cells J Clin Invest 118 3038 3050 18704194 10.1172/JCI33337 1:CAS:528:DC%2BD1cXhtV2isb3M
14. SY Sun LM Rosenberg X Wang, et al. 2005 Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition Cancer Res 65 7052 7058 16103051 10.1158/0008-5472.CAN-05-0917 1:CAS:528:DC%2BD2MXns1Wrt7c%3D (Pubitemid 41161231)
15. J Tamburini N Chapuis V Bardet, et al. 2008 Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways Blood 111 379 382 17878402 10.1182/blood-2007-03-080796 1:CAS:528:DC%2BD1cXjtVKmtQ%3D%3D
16. A Carracedo L Ma J Teruya-Feldstein, et al. 2008 Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J Clin Invest 118 3065 3074 18725988 1:CAS:528:DC%2BD1cXhtV2isb3P
17. CW Kinkade M Castillo-Martin A Puzio-Kuter, et al. 2008 Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model J Clin Invest 118 3051 3064 18725989 1:CAS:528:DC%2BD1cXhtV2isb3N
18. ZY Wang Z Chen 2008 Acute promyelocytic leukemia: from highly fatal to highly curable Blood 111 2505 2515 18299451 10.1182/blood-2007-07-102798 1:CAS:528:DC%2BD1cXivFaktrg%3D
19. K Petrie A Zelent S Waxman 2009 Differentiation therapy of acute myeloid leukemia: past, present and future Curr Opin Hematol 16 84 91 19468269 10.1097/MOH.0b013e3283257aee 1:CAS:528:DC%2BD1MXntFyks78%3D
20. K Matkovic F Brugnoli V Bertagnoli, et al. 2006 The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-differentiated HL-60 cells Leukemia 20 941 951 16617325 10.1038/sj.leu.2404204 1:CAS:528:DC%2BD28XkvVymtbY%3D (Pubitemid 43797283)
21. C Nishioka T Ikezoe J Yang, et al. 2009 Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells Int J Cancer 125 1710 1720 19507250 10.1002/ijc.24472 1:CAS:528: DC%2BD1MXpsVKmsLg%3D
22. K Matkovic V Lukinovic-Skudar H Banfic, et al. 2009 The activity of extracellular signal-regulated kinase is required during G2/M phase before metaphase-anaphase transition in synchronized leukemia cell lines Int J Hematol 89 159 166 19148588 10.1007/s12185-008-0248-3 1:CAS:528:DC%2BD1MXis1Glu7w%3D
23. EM Breslin PC White AM Shore, et al. 2005 LY294002 and rapamycin co-operate to inhibit T-cell proliferation Br J Pharmacol 144 791 800 15778701 10.1038/sj.bjp.0706061 1:CAS:528:DC%2BD2MXisVGjsrs%3D (Pubitemid 40516119)
24. T Ikezoe C Nishioka K Bandobashi, et al. 2007 Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells Leuk Res 31 673 682 17007924 10.1016/j.leukres.2006.08. 001 1:CAS:528:DC%2BD2sXkt1aqsbc%3D (Pubitemid 46560001)
25. S Scholl T Bondeva Y Liu, et al. 2008 Additive effects of PI3-kinase and MAPK activities on NB4 cell granulocyte differentiation: potential role of phosphatidylinositol 3-kinase gamma J Cancer Res Clin Oncol 134 861 872 18288489 10.1007/s00432-008-0356-8 1:CAS:528:DC%2BD1cXmslWksb0%3D
26. A Yen MS Roberson S Varvayanis, et al. 1998 Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest Cancer Res 58 3163 3172 9679985 1:CAS:528:DyaK1cXkvVCmtrw%3D (Pubitemid 28335101)
27. kip1 in PMA-induced differentiation of HL-60 cells FEBS Lett 472 50 52 10781803 10.1016/S0014-5793(00)01416-2 1:CAS:528:DC%2BD3cXislars7k%3D (Pubitemid 30224584)
28. MB Miranda TF McGuire DE Johnson 2002 Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines Leukemia 16 683 692 11960350 10.1038/sj.leu.2402400 1:CAS:528:DC%2BD38XjvFGmsrk%3D (Pubitemid 34449751)
29. T Crabbe MJ Welham SG Ward 2007 The PI3K inhibitor arsenal: choose your weapon! Trends Biochem Sci 32 450 456 17920279 10.1016/j.tibs.2007.09.001 1:CAS:528:DC%2BD2sXhtF2lsbrI (Pubitemid 47588944)
30. F Chiarini F Falà PL Tazzari, et al. 2009 Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia Cancer Res 69 3520 3528 19351820 10.1158/0008-5472.CAN-08-4884 1:CAS:528:DC%2BD1MXksV2htrc%3D
31. S Park N Chapuis V Bardet, et al. 2008 PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML Leukemia 22 1698 1706 18548104 10.1038/leu.2008.144 1:CAS:528: DC%2BD1cXhtVyqu7%2FK
32. V Bertagnolo LM Neri M Marchisio, et al. 1999 Phosphoinositide 3-kinase activity is essential for all-trans-retinoic acid-induced granulocytic differentiation of HL-60 cells Cancer Res 59 542 546 9973197 1:CAS:528:DyaK1MXhtV2rs78%3D (Pubitemid 29076047)
33. L Lal Y Li J Smith, et al. 2005 Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells Blood 105 1669 1677 15471950 10.1182/blood-2004-06-2078 1:CAS:528:DC%2BD2MXhsVChurk%3D (Pubitemid 40223689)
34. N Hay 2005 The Akt-mTOR tango and its relevance to cancer Cancer Cell 8 179 183 16169463 10.1016/j.ccr.2005.08.008 1:CAS:528:DC%2BD2MXhtV2gt7rL (Pubitemid 41317589)
35. SJ Park SY Kang NS Kim, et al. 2002 Phosphatidylinositol 3-kinase regulates PMA-induced differentiation and superoxide production in HL-60 cells Immunopharmacol Immunotoxicol 24 211 226 12066848 10.1081/IPH-120003751 1:CAS:528:DC%2BD38Xlt1SjsLc%3D (Pubitemid 34596513)